Litcius/Paper detail

Sulbactam-durlobactam: A Step Forward in Treating Carbapenem-Resistant <i>Acinetobacter baumannii</i> (CRAB) Infections

Richard Watkins, Robert A. Bonomo

2023Clinical Infectious Diseases31 citationsDOIOpen Access PDF

Abstract

Antimicrobial resistance in gram-negative pathogens, such as Acinetobacter baumannii, is a serious threat to human health. Sulbactam-durlobactam, a unique β-lactam and a β-lactamase inhibitor combination, is a novel agent targeted against carbapenem-resistant A. baumannii. This supplement provides a summary of the development of SUL-DUR, discussing its unique features and role in treating infections caused by CRAB pathogens.

Topics & Concepts

Acinetobacter baumanniiSulbactamMedicineMicrobiologyAntimicrobialCarbapenemAcinetobacterAntibiotic resistanceAntibioticsBacteriaBiologyPseudomonas aeruginosaImipenemGeneticsAntibiotic Resistance in BacteriaAntibiotic Use and ResistanceAntibiotics Pharmacokinetics and Efficacy
Sulbactam-durlobactam: A Step Forward in Treating Carbapenem-Resistant <i>Acinetobacter baumannii</i> (CRAB) Infections | Litcius